Active, not recruitingPHASE1, PHASE2NCT05141682
Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia
Studying T-cell large granular lymphocyte leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Jonathan Brammer
- Principal Investigator
- Jonathan Brammer, MDOhio State University Comprehensive Cancer Center
- Intervention
- Oral Azacitidine(drug)
- Enrollment
- 11 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2026
Study locations (2)
- Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
- University of Virginia, Charlottesville, Virginia, United States
Collaborators
Bristol-Myers Squibb
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05141682 on ClinicalTrials.govOther trials for T-cell large granular lymphocyte leukemia
Additional recruiting or active studies for the same condition.
See all trials for T-cell large granular lymphocyte leukemia →